chr1-155235256-C-T
Variant summary
Our verdict is Benign. Variant got -13 ACMG points: 0P and 13B. BP4_StrongBP6BS1BS2
The NM_000157.4(GBA1):c.1444G>A(p.Asp482Asn) variant causes a missense change involving the alteration of a non-conserved nucleotide. The variant allele was found at a frequency of 0.000423 in 1,613,852 control chromosomes in the GnomAD database, including 4 homozygotes. In-silico tool predicts a benign outcome for this variant. 14/21 in silico tools predict a benign outcome for this variant. Variant has been reported in ClinVar as Conflicting classifications of pathogenicity (no stars).
Frequency
Consequence
NM_000157.4 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Benign. Variant got -13 ACMG points.
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
GBA1 | NM_000157.4 | c.1444G>A | p.Asp482Asn | missense_variant | 10/11 | ENST00000368373.8 | NP_000148.2 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
GBA1 | ENST00000368373.8 | c.1444G>A | p.Asp482Asn | missense_variant | 10/11 | 1 | NM_000157.4 | ENSP00000357357 | P1 |
Frequencies
GnomAD3 genomes AF: 0.00211 AC: 321AN: 152072Hom.: 2 Cov.: 26
GnomAD3 exomes AF: 0.000522 AC: 131AN: 251124Hom.: 1 AF XY: 0.000413 AC XY: 56AN XY: 135726
GnomAD4 exome AF: 0.000247 AC: 361AN: 1461662Hom.: 2 Cov.: 32 AF XY: 0.000212 AC XY: 154AN XY: 727140
GnomAD4 genome AF: 0.00212 AC: 322AN: 152190Hom.: 2 Cov.: 26 AF XY: 0.00203 AC XY: 151AN XY: 74410
ClinVar
Submissions by phenotype
not provided Uncertain:1Benign:2
Likely benign, criteria provided, single submitter | clinical testing | CeGaT Center for Human Genetics Tuebingen | Apr 01, 2023 | GBA1: BS2 - |
Likely benign, criteria provided, single submitter | clinical testing | GeneDx | Sep 23, 2020 | This variant is associated with the following publications: (PMID: 20425034, 21242499, 19502295, 26296077, 25249066, 19286695) - |
Uncertain significance, criteria provided, single submitter | clinical testing | Mayo Clinic Laboratories, Mayo Clinic | Oct 05, 2022 | BS1 - |
not specified Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Jan 06, 2020 | Variant summary: GBA c.1444G>A (p.Asp482Asn) results in a conservative amino acid change located in the Glycosyl hydrolase family 30, beta sandwich domain (IPR033452) of the encoded protein sequence. Four of five in-silico tools predict a benign effect of the variant on protein function. The variant allele was found at a frequency of 0.00052 in 253860 control chromosomes, predominantly at a frequency of 0.0075 within the African or African-American subpopulation in the gnomAD database, including 1 homozygote. The observed variant frequency within African or African-American control individuals in the gnomAD database is approximately 1.5 fold of the estimated maximal expected allele frequency for a pathogenic variant in GBA causing Gaucher Disease phenotype (0.005), strongly suggesting that the variant is a benign polymorphism found primarily in populations of African or African-American origin. c.1444G>A has been reported in the literature in individuals affected with Parkinson's disease (e.g. Asselta_2014, Gan-Or_2015, Neumann_2009). These reports however, do not provide unequivocal conclusions about association of the variant with Gaucher Disease. It was reported in the literature that GBA mutations may be a risk factor for Parkinson's disease (e.g. PMIDs: 19502295, 26860875). To our knowledge, no experimental evidence demonstrating an impact on protein function has been reported. No clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. Based on the evidence outlined above, the variant was classified as likely benign. - |
Gaucher disease type II;C0268251:Gaucher disease type III;C0752347:Lewy body dementia;C1842704:Gaucher disease perinatal lethal;C1856476:Gaucher disease-ophthalmoplegia-cardiovascular calcification syndrome;C1961835:Gaucher disease type I;C3160718:Parkinson disease, late-onset Benign:1
Likely benign, criteria provided, single submitter | clinical testing | Fulgent Genetics, Fulgent Genetics | Feb 23, 2022 | - - |
Gaucher disease Benign:1
Likely benign, no assertion criteria provided | clinical testing | Natera, Inc. | Nov 14, 2017 | - - |
Parkinson disease, late-onset Other:1
risk factor, no assertion criteria provided | literature only | OMIM | Jul 01, 2009 | - - |
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at